-transparent.png){kind=logo}
A phase II study of spirogermanium was conducted in a series of 15 patients with metastatic prostatic carcinoma. All the patients have previously received multiple hormonal therapies. The drug was administered at the dose of 200 mg/m2 by a continuous infusion for five days, and 120 mg/m2, three times a week subsequently. The side effects were mainly neurological toxicity and phlebitis at the injection points which were dose and schedule dependent. Only one partial response for two months was noted in this series. Thus, spirogermanium seems to have a limited value in patients with prostatic cancer.
Related Publications
N B Bui, and
J Chauvergne, and
R Brunet, and
P Richaud, and
B Hoerni, and
C Lagarde, and
M Le Guillou
May 1990,
Investigational new drugs,
N B Bui, and
J Chauvergne, and
R Brunet, and
P Richaud, and
B Hoerni, and
C Lagarde, and
M Le Guillou
September 1986,
Cancer treatment reports,
N B Bui, and
J Chauvergne, and
R Brunet, and
P Richaud, and
B Hoerni, and
C Lagarde, and
M Le Guillou
September 1984,
Cancer treatment reports,
N B Bui, and
J Chauvergne, and
R Brunet, and
P Richaud, and
B Hoerni, and
C Lagarde, and
M Le Guillou
December 1984,
Cancer treatment reports,
N B Bui, and
J Chauvergne, and
R Brunet, and
P Richaud, and
B Hoerni, and
C Lagarde, and
M Le Guillou
February 1993,
Investigational new drugs,
N B Bui, and
J Chauvergne, and
R Brunet, and
P Richaud, and
B Hoerni, and
C Lagarde, and
M Le Guillou
December 1987,
Cancer treatment reports,
N B Bui, and
J Chauvergne, and
R Brunet, and
P Richaud, and
B Hoerni, and
C Lagarde, and
M Le Guillou
November 2003,
Investigational new drugs,
N B Bui, and
J Chauvergne, and
R Brunet, and
P Richaud, and
B Hoerni, and
C Lagarde, and
M Le Guillou
February 2003,
Investigational new drugs,
N B Bui, and
J Chauvergne, and
R Brunet, and
P Richaud, and
B Hoerni, and
C Lagarde, and
M Le Guillou
January 1981,
Cancer treatment reports,
N B Bui, and
J Chauvergne, and
R Brunet, and
P Richaud, and
B Hoerni, and
C Lagarde, and
M Le Guillou
August 2003,
Investigational new drugs,
